Illumina (ILMN) : Tuesdays money flow points at investors jumping to buy the stock on the weakness of price. $31.87 million worth of transactions were on upticks, whereas, the downticks accounted for $20.86 million worth of transactions. The net money flow was a positive $11.01 million and the uptick to downtick ratio was 1.53. The net money flow into the stock was $8.69 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $8.69 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Illumina (ILMN) was trading at $168.99, down $1.43 during day. The stock slid -0.84% over the previous days close. For the week, the stock recorded -1.87% over the previous weeks close.
Also, In a research note released to the investors, CL King downgrades its rating on Illumina (NASDAQ:ILMN).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 22, 2016.
Illumina Inc. has lost 2.2% in the last five trading days and dropped 0.97% in the last 4 weeks. Illumina Inc. is up 15.92% in the last 3-month period. Year-to-Date the stock performance stands at -11.96%.
Illumina (NASDAQ:ILMN): The stock opened at $170.50 on Tuesday but the bulls could not build on the opening and the stock topped out at $170.99 for the day. The stock traded down to $167.89 during the day, due to lack of any buying support eventually closed down at $168.99 with a loss of -0.84% for the day. The stock had closed at $170.42 on the previous day. The total traded volume was 577,128 shares.
In a related news, The director, of Illumina Inc, Bradbury Daniel had unloaded 600 shares at $168.42 per share in a transaction on August 17, 2016. The total value of transaction was $101,052. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.